Product Information
Registration Status: ActiveSIN06047P
ORCIGESIC TABLET is approved to be sold in Singapore with effective from 1991-05-24. It is marketed by SUNWARD PHARMACEUTICAL PTE LTD, with the registration number of SIN06047P.
This product contains Mefenamic Acid 250mg, and Orphenadrine 35mg in the form of TABLET, FILM-COATED. It is approved for ORAL use.
This product is manufactured by SUNWARD PHARMACEUTICAL PTE LTD in SINGAPORE.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Description
A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase. [PubChem]
Indication
For the treatment of rheumatoid arthritis, osteoarthritis, dysmenorrhea, and mild to moderate pain, inflammation, and fever.
Mechanism of Action
Mefenamic acid binds the prostaglandin synthetase receptors COX-1 and COX-2, inhibiting the action of prostaglandin synthetase. As these receptors have a role as a major mediator of inflammation and/or a role for prostanoid signaling in activity-dependent plasticity, the symptoms of pain are temporarily reduced.
Pharmacokinetics
- Absorption
- Mefenamic acid is rapidly absorbed after oral administration.
- Distribution
- * 1.06 L/kg [Normal Healthy Adults (18-45 yr)]
- Metabolism
- Mefenamic acid undergoes metabolism by CYP2C9 to 3-hydroxymethyl mefenamic acid, and further oxidation to a 3-carboxymefenamic acid may occur. The activity of these metabolites has not been studied. Mefenamic acid is also glucuronidated directly.
- Elimination
Clearance
* Oral cl=21.23 L/hr [Healthy adults (18-45 yrs)]
Toxicity
Oral, rat LD50: 740 mg/kg. Symptoms of overdose may include severe stomach pain, coffee ground-like vomit, dark stool, ringing in the ears, change in amount of urine, unusually fast or slow heartbeat, muscle weakness, slow or shallow breathing, confusion, severe headache or loss of consciousness.
Active Ingredient/Synonyms
Acide méfénamique | Acido mefenamico | Acidum mefenamicum | CN 35355 | INF 3355 | Mefenaminsaeure | Mefenaminsäure | N-(2,3-Xylyl)-2-aminobenzoic acid | N-2,3-Xylylanthranilic acid | Mefenamic acid |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.
Description
A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm. [PubChem]
Indication
Indicated for the treatment of Parkinson's disease.
Mechanism of Action
Orphenadrine binds and inhibits both histamine H1 receptors and NMDA receptors. It restores the motor disturbances induced by neuroleptics, in particular the hyperkinesia. The dopamine deficiency in the striatum increases the stimulating effects of the cholinergic system. This stimulation is counteracted by the anticholinergic effect of orphenadrine. It may have a relaxing effect on skeletal muscle spasms and it has a mood elevating effect.
Pharmacokinetics
- Absorption
- Orphenadrine is almost completely absorbed in the gastrointestinal tract.
- Distribution
- Metabolism
- Biotransformation occurs mainly in the liver. Pharmacologically active metabolites are N-demethyl orphenadrine and N,N-didemethyl orphenadrine.
- Elimination
Toxicity
Oral, mouse LD50 = 100 mg/kg; oral, rat LD50 = 255 mg/kg
Active Ingredient/Synonyms
2-(phenyl-o-tolylmethoxy)ethyldimethylamine | 2-methyldiphenhydramine | beta-Dimethylaminoethyl 2-methylbenzhydryl ether | Dimethyl-[2-(phenyl-O-tolyl-methoxy)-ethyl]-amine | N,N-Dimethyl-2-(alpha-2-tolylbenzoyloxy)ethylamine | N,N-Dimethyl-2-(phenyl(O-tolyl)methoxy)ethanamine | N,N-Dimethyl-2-[(O-methyl-alpha-phenylbenzyl)oxy]ethylamine | o-methyldiphenhydramine | o-monomethyldiphenhydramine | Orfenadrina | ORPHENADRINE | Orphenadrinum | Phenyl-O-tolylmethyl dimethyaminoethyl ether | β-dimethylaminoethyl 2-methylbenzhydryl ether | Orphenadrine |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.